Related references
Note: Only part of the references are listed.Increased mTOR activation in idiopathic multicentric Castleman disease
Daniel J. Arenas et al.
BLOOD (2020)
The French paediatric cohort of Castleman disease: a retrospective report of 23 patients
Charlotte Borocco et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease
Ruth-Anne Langan Pai et al.
JCI INSIGHT (2020)
A pediatric case of tocilizumab-resistant TAFRO syndrome treated successfully with rituximab
Shogo Minamikawa et al.
PEDIATRIC BLOOD & CANCER (2020)
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
Frits van Rhee et al.
BLOOD ADVANCES (2020)
Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study
Jenna Sopfe et al.
PEDIATRIC BLOOD & CANCER (2019)
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade-refractory idiopathic multicentric Castleman disease
David C. Fajgenbaum et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease
David C. Fajgenbaum et al.
BLOOD (2017)
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease
Noriko Iwaki et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version
Yasufumi Masaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease
Ikuko Kubokawa et al.
BMC PEDIATRICS (2014)
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
Frits van Rhee et al.
LANCET ONCOLOGY (2014)
Castleman-Kojima Disease (TAFRO Syndrome) : A Novel Systemic Inflammatory Disease Characterized by a Constellation of Symptoms, Namely, Thrombocytopenia, Ascites (Anasarca), Microcytic Anemia, Myelofibrosis, Renal Dysfunction, and Organomegaly : A Status Report and Summary of Fukushima (6 June, 2012) and Nagoya Meetings (22 September, 2012)
Hiroshi Kawabata et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2013)
Share Paper
